GlassScriptPhysician profile
Paul A Dibiase
NPI 1407935000
$1,538.21
in general payments reported to CMS, 2019-2025
17 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Plastic Surgery Within The Head & Neck provider received nationally (typical 2025 total: $238).
See the full distribution for Plastic Surgery within the Head & Neck
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $61.19 · 2021: $96.86 · 2022: $290 · 2023: $239 · 2024: $433 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.83 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $437.64 | 2022-2025 | |
| Glaxosmithkline, LLC. | $283.48 | 2023-2025 | Nucala |
| Optinose US, INC. | $222.88 | 2019-2023 | |
| Inspire Medical Systems, INC. | $158.37 | 2022 | |
| Stryker Corporation | $82.70 | 2020-2024 | Clarifix Cryotherapy Device, Audion Et Dilation System |
| Aerin Medical INC. | $55.78 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Csl Behring | $47.15 | 2019 | |
| Smith+Nephew, INC. | $46.98 | 2024-2025 | Stravix Pl |
| Intersect Ent, INC. | $26.15 | 2021 | |
| Acclarent, INC | $22.12 | 2021 | |
| Checkpoint Surgical, INC | $19.46 | 2019 | |
| Abbott Laboratories | $19.05 | 2025 | Amplatzer Amulet |
| Merck Sharp & Dohme LLC | $17.94 | 2025 | Keytruda |
| Alk-Abello, INC | $16.52 | 2024 | Pre-Pen |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.16 | 2024 | Airsupra |
| Hikma Pharmaceuticals USA | $12.88 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dibiase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.